NVO Stock Recent News
NVO LATEST HEADLINES
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Much like the long-term users of its most popular product, Novo Nordisk's (NVO 0.69%) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share.
It won't come as a surprise to anyone to hear that quite a few quality stocks have performed terribly this year. Some have encountered company-specific problems, others have been swept up in the market's volatility, and for others still, it's a combination of the two.
Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track.
Novo Nordisk's sharp 54% decline is driven by LLY's competition, regulatory issues, and leadership change, but its fundamentals remain robust. Despite recent setbacks, NVO continues to deliver strong revenue, profit growth, and high economic profitability, trading well below intrinsic value. The removal of compounded alternatives and new leadership present strategic opportunities for the Company to regain market share and momentum.
Nothing attracts competition like the opportunity for profits, and the weight loss drug market has become arguably the healthcare industry's hottest opportunity in recent memory. Novo Nordisk (NVO 4.53%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy.